Kornimate/medical-research-clean huggingface dataset:
microdecompression versus open laminectomy and posterior stabilization for multilevel lumbar spine stenosis

Conditions: Lumbar Spinal Stenosis

Summary: this study compare the results of 2 methods in surgical treatment of lumbar spine stenosis.these are microdecompresssion and open decompression with posterior stabilization. 100 patients are involved in this study who divided in 2 groups.each group was treated with one method and follow up done which showed both method are effective with better results in those patients treated with microdecomppression.

this randomized controlled study was conducted between january 2016 and october 2018. one hundred patients were involved in this study. all these patients were suffered from radicular leg pain with mri features of multilevel lumbar spinal stenosis and were treated by conservative treatment of medical treatment and physiotherapy without benefit for (6) months. those patients were divided into two groups; group a, (50) microdecompression, and group b, (50) patients who were treated by open wide laminectomy and posterior stabilization. both groups of patients were followed up with odi (oswestry disability index) and vas (visual analogue score) for the back and leg pain for one year. results: the results showed that both groups got significant improvement regarding oswestry disability index. regarding back pain, there was a significant improvement in both groups with better results in-group a due minimal tissues injury as the advantage of minimal invasive technique. in both groups, there were marked improvement of radicular leg pain postoperatively. conclusions: both microdecompression and wide open laminectomy with posterior stabilization were effective in treatment of multilevel lumbar spinal stenosis with superior results of microdecompression regarding less back pain postoperatively with less blood loss and soft tissue dissection.

Eligibility criteria:
inclusion criteria: * patients were suffered from back pain of different degrees with spinal claudication exclusion criteria: * smoking * diabetic patients, * previous spinal surgery, * any neuromuscular disorder like poliomyelitis, and * vertebral instability proved by dynamic plain radiographs

Keywords: microdecompression laminectomy pain stenosis
long-term blood pressure outcome after unilateral adrenalectomy for primary hyperaldosteronism

Conditions: Adrenalectomy; Status

Summary: to evaluate long-term results of adrenalectomy for primary aldosteronism (pa) and to identify prognostic factors associated. exhaustive retrospective review of all consecutive patients undergoing adrenalectomy for pa between 2002 and 2013 in our department. all patients underwent preoperative: clinical evaluation (age, sex, height, weight, systolic and diastolic bp under treatment, identification of anti-hypertension treatment), biological evaluation (potassium, renin, aldosterone) and radiological evaluation (ct and/or mri). blood pressure was assessed postoperatively at 1 month, 1 year, then at the date of the latest news. the patients were classified into three categories: cured (no antihypertensive therapy in postoperative associated with strictly lower blood pressures of 140/90mmhg), improved (decreased number of drugs or number unchanged but with better blood pressure control), and refractory (no change in the number of drug and blood pressure, or deterioration of one or other of these two parameters).

to evaluate long-term results of adrenalectomy for primary aldosteronism (pa) and to identify prognostic factors associated.exhaustive retrospective review of all consecutive patients undergoing adrenalectomy for pa between 2002 and 2013 in our department. all patients underwent preoperative: clinical evaluation (age, sex, height, weight, systolic and diastolic bp under treatment, identification of anti-hypertension treatment), biological evaluation (potassium, renin, aldosterone) and radiological evaluation (ct and/or mri). blood pressure was assessed postoperatively at 1 month, 1 year, then at the date of the latest news. the patients were classified into three categories: cured (no antihypertensive therapy in postoperative associated with strictly lower blood pressures of 140/90mmhg), improved (decreased number of drugs or number unchanged but with better blood pressure control), and refractory (no change in the number of drug and blood pressure, or deterioration of one or other of these two parameters).

Eligibility criteria:
inclusion criteria: * patients \>25 years and \<80 years patients undergoing adrenalectomy for pa * all patients underwent preoperative: clinical evaluation (age, sex, height, weight, systolic and diastolic bp under treatment, identification of anti-hypertension treatment), biological evaluation (potassium, renin, aldosterone) and radiological evaluation (ct and/or mri). exclusion criteria: * patients \<25 years * patients \> 80 years

Keywords: blood pressure
long-term effects of visual spatial working memory training program performed at preschool age in very preterm infants with visual spatial working memory deficit. a randomized controlled trial

Conditions: Children Born Extremely Premature; Disturbance of Visuo-spatial Working Memory

Summary: prematurity tends to increase in france in recent years and more children born extremely premature infants survive. if severe impairments have stabilized, the majority of former extremely premature children have neuropsychological disorders and moderate appearance behavior disorder, but with a significant impact both family, school and social persisting into adulthood. executive functions (ef), in general, and working memory (mt), in particular, are frequently altered in older children preterm infants compared to controls born at term. the identification process of loss in certain diseases, as well as improving knowledge of brain functioning, and development with the possibility of neuronal plasticity has led research teams to develop intervention programs focused on process cognitive qualified of "remediation" cognitive (rc). schematically, the rc is defined as a rehabilitation or altered cognitive functions. mt can be improved by encouraging the operation of the spots mental stimulant. these programs are effective on mt but do not have the expected impact on other fe, language or nonverbal functions (visuospatial). the functional benefit of cognitive remediation remains controversial. improving mental functions untrained as nonverbal mt, attention and secondarily learning is possible but still unproven on wide population. similarly, randomized trials are needed to test this type of cognitive remediation among preschoolers old very premature.


Eligibility criteria:
inclusion criteria: * already included in the study epipage 2, born between 24 and 34 weeks' ga (gestational amenorrhea), * children aged 5 to 6 years, * children exhibiting a total intellectual quotient \>70 from the wppsi iv (during the 5-year assessment in epipage 2), * children having a visuo-spatial working memory impairment defined by a working memory index \<85 from the wppsi iv, * children with parents (or legal guardians) authorizing participation in the study and a signed informed consent form, * children affiliated with medical insurance. exclusion criteria: * children with severe cerebral palsy, based on the gross motor function (gmfcs score \>2) and bimanual fine motor function (bfmf \>2) classification system (elvrum ag 2015, marois p 2015), * children with blindness or amblyopia, defined by a visual acuity \<3 (during the 5-year assessment in epipage 2), * children with deafness, as defined by a prescribed hearing aid, * children with chromosomal disorder or autistic syndrome, * children included in the epilang study protocol (an ancillary project to epipage), * children who do not speak french * children with parents having no internet connection, * triplets.
improving attention deficit hyperactivity disorder treatment adherence and outcome in primary care settings

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: this study will determine the effectiveness of educating pediatricians about attention deficit hyperactivity disorder treatment guidelines in improving child behavior and pediatricians' adherence to medication guidelines.

the most effective treatment for improving the core symptoms of inattention, impulsivity and hyperactivity in children with attention deficit hyperactivity disorder (adhd) involves the use of stimulant medications. most children with adhd are treated by pediatricians, but the treatment provided is often less than optimal. this study is designed to see if training for pediatricians in following guidelines for management of first-line medicines for adhd leads to improvement in child behavior, and whether the physicians can adhere to the guidelines. over 100 studies have shown that stimulant medications are effective for improving the core symptoms of attention deficit hyperactivity disorder (adhd). approximately 70% of children who receive adhd medications are treated by their primary care pediatrician, but studies show that management is not always optimal. the present study is designed to see if child behavior can be improved by training pediatricians in the use of guidelines for treating adhd, and whether the physicians can adhere to the guidelines. twenty-four pediatric practices were randomized to a treatment as usual or specialized care (receiving training in guidelines and computer assisted monitoring of patient progress and medication titration). children are assessed with parent and teacher reports at baseline, 4-, 9-, and 12-months post initiation of treatment, and classroom observations of behavior are assessed at baseline, 6-, and 12-months. approximately 400 children are to be enrolled.

Eligibility criteria:
inclusion criteria: * presence of adhd * not currently on medication exclusion criteria: * no serious neurological disorders of sever mental health problems (suicidal behavior, autism)

Keywords: adhd attention deficit hyperactivity disorder
standard pcnl vs endoscopic combined intrarenal surgery (ecirs) for complex nephrolithiasis in obese patients

Conditions: Renal Stone

Summary: primary aim: comparing the efficacy of standard pcnl and endoscopic combined intrarenal surgery (ecirs) in the galdakao-modified supine valdivia (gmsv) position in a single session for the treatment of complex nephrolithiasis in obese patients. secondary aim: comparing safety and complications of standard pcnl and ecirs in the gmsv.

complex nephrolithiasis including multiple peripheral or branched (partial or complete staghorn calculi) renal stones, is still currently an intractable problem for urologists to achieve stone-free status and minimize complication rates. according to the european association of urology urolithiasis guidelines, retrograde intrarenal surgery (rirs) is recommended as first-line treatment for renal stones \< 2 cm, and percutaneous nephrolithotomy (pcnl) is recommended as the gold standard for renal stones ≥ 2 cm in length. obesity has been identified as an independent risk factor for stone formation in the united states. obesity (bmi \>35) also places surgical patients at a greater risk of complications, because of the increased incidence in this group of diabetes, hypertension, ischemic heart disease, postoperative deep venous thrombosis, and pulmonary embolism, and because of poor radiographic visualization, obscure anatomic landmarks, more difficult renal access, and inferior stone-free rates. standard percutaneous nephrolithotomy (pcnl) is the recommended treatment by major guidelines. however, multiple tracts or sessions of pcnl were required to obtain a high stone-free rate (sfr) for complex renal calculi, especially staghorn stones, while procedure-related complications increased concomitantly. to acquire a higher sfr, full access to the entire intrarenal collecting system is the final goal of treatment for these patients suffering from multiple calyceal or peripheral satellite calculi, which is technically challenging by means of rirs or pcnl monotherapy.

Eligibility criteria:
inclusion criteria: * partial or complete staghorn stones) * guy's stone score iii or iv) * adult (18-60) years old patients * obese \& super-obese patients (bmi \> 30 kg/m 2). exclusion criteria: * patients with congenital renal anomalies

Keywords: ecirs pcnl obese
observational study in patients with schizophrenia treated with long-acting risperidone injection (risperdal consta)

Conditions: Schizophrenia

Summary: the purpose of this study is to examine treatment practices of adult schizophrenia patients by their own doctors, and to assess patient outcomes when treated with long-acting risperidone injection over a two-year period of observation.

this is a 2-year, prospective (a study in which the patients are identified and then followed forward in time for the outcome of the study), multi-center (at multiple sites), longitudinal (study that involves repeated observations of the same outcomes in the same people over long periods of time), observational study (study in which the investigators/ physicians observe the patients and measure their outcomes) in adults with schizophrenia (mental disorder characterized by a breakdown of thought processes and by poor emotional responsiveness). physicians will determine the appropriate treatment for their patients, according to their usual practice. patients starting treatment with long-acting risperidone injection (an antipsychotic medication) and meeting all the study criteria will be enrolled in the study. they will receive a dose of 25, 37.5 or 50 mg of risperidone every 2 weeks by intramuscular injection, and continue their treatment for schizophrenia according to usual care by their physicians. patients will be asked questions at baseline and every three months for a period of two years to assess: efficacy of the medication, how well the patient is functioning, use of healthcare resources (eg, emergency room visits and hospitalizations) patient work status, quality of life and patient satisfaction with the medicine. safety will be monitored throughout the study duration of 2 years.

Eligibility criteria:
inclusion criteria: * patients had schizophrenia (disorganized, catatonic, paranoid, residual, or undifferentiated) that met disease diagnostic criteria as defined in diagnostic and statistical manual of mental disorders iv (\[dsm-iv\] * requiring new treatment with long-acting risperidone injectable * patients were cooperative, reliable, and able to complete all aspects of the protocol exclusion criteria: * use of an investigational drug in the past 30 days * at risk to self or others

Keywords: schizophrenia mental disorder dsm-iv risperdal consta risperidone long-acting risperidone disorganized catatonic paranoid
ceftaroline pharmacokinetics in continuous renal replacement therapy

Conditions: Infection During Renal Replacement Therapy; Critically Ill

Summary: dosing of ceftaroline in patients with chronic kidney disease is defined, but there is no data on pharmacokinetics and pharmacodynamics of the drug in patients receiving continuous renal replacement therapy (crrt). the purpose of this study is to determine pharmacokinetics and pharmacodynamics of ceftaroline in a critically ill patient population receiving crrt, in order to define a dosing recommendation in this population.

ceftaroline fosamil is a time-dependent, hydrophilic, bactericidal fifth generation cephalosporin that was fda approved in 2010 for community acquired pneumonia and skin and skin structure infections. ceftaroline is fda approved for both gram-positive and gram-negative organisms. gram-positive organisms covered are staphylococcus aureus (methicillin resistant and methicillin sensitive strains), streptococcus agalactiae, streptococcus pneumonia, and streptococcus pyogenes. gram-negative coverage includes escherichia coli, haemophilus influenza, klebsiella pneumonia, and klebsiella oxytoca. in order for ceftaroline to exhibit effective bacterial killing, it requires that a certain percentage of the dosing interval is spent above the mic. dosing of ceftaroline in patients with chronic kidney disease is defined, but there is no data on pharmacokinetics and pharmacodynamics of the drug in patients receiving continuous renal replacement therapy (crrt). the purpose of this study is to determine pharmacokinetics and pharmacodynamics of ceftaroline in a critically ill patient population receiving crrt, in order to define a dosing recommendation in this population. crrt modes that patients may be receiving in this trial include: continuous veno-venous hemofiltration (cvvh), continuous veno-venous hemodialysis (cvvhd), and continuous veno-venous hemodiafiltration (cvvhdf).

Eligibility criteria:
inclusion criteria: * admitted to an intensive care unit * receiving crrt (cvvh, cvvhdf, cvvhd) * receiving ceftaroline exclusion criteria: * pregnant patients * burn patients * patients with toxic epidermal necrolysis or stevens-johnson syndrome * patients prescribed extended infusion ceftaroline
a phase 2 study of ruxolitinib with chemotherapy in children with acute lymphoblastic leukemia

Conditions: Leukemia

Summary: this is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of b-cell acute lymphoblastic leukemia. part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in part 1.


Eligibility criteria:
inclusion criteria: * eligible for study when participant is 1 year to 21 years at the time of diagnosis * eligible ages in canada; 2 years to 21 years * de novo high-risk (hr) ph-like b-all for which any of following criteria are present at diagnosis: * age ≥ 10 years * white blood cell (wbc) ≥ 50 × 10\^3/μl * cns3 leukemia at diagnosis * systemic steroid pretreatment without presteroid wbc documentation * diagnostic bone marrow or peripheral blood sample must have gene expression profiling and downstream genetic testing performed by submitting diagnostic specimens under the cog aall08b1 or apec14b1 biology studies, or aall1131 or its successor study. specimens must demonstrate a ph-like expression profile (ie, lda-positive) as tested by low density microarray testing at the cog all reference laboratory or tricore laboratory at the university of new mexico and must contain 1 of the following genetic lesions: (determined at cog all reference laboratories, or equivalent cap/clia-certified laboratories approved by the medical monitor: 1. crlf2 rearrangement with confirmed jak1 or jak2 mutation (jak+) 2. crlf2 rearrangement without jak mutation 3. other jak pathway alterations (eg, jak2 fusions, epor fusions, sh2b3 deletions, il7ra mutations) with or without crlf2-r, or crlf2-r with unknown jak status as determined by a cog all reference laboratory * completed a 4-drug induction therapy regimen (modified abfm regimen or equivalent) in study aall1131 or its successor study, or as per the institutional standard of care for hr b-all and have had end-induction minimal residual disease (mrd) assessed * male and female subjects of reproductive non childbearing potential or willing to take appropriate precautions to avoid pregnancy or fathering a child for the duration of study participation exclusion criteria: * receipt of any other cytotoxic chemotherapy before induction therapy, with exception of hydroxyurea or steroid pretreatment * trisomy 21 (down syndrome) * bcr-abl1-rearranged (ph+) all * calculated creatinine clearance or radioisotope glomerular filtration rate \< 70 ml/min/1.73 m\^2 * alanine aminotransferase ≥ 5 × upper limit of normal (uln) for age * direct bilirubin ≥ 1.5 × uln (may be assumed if total bilirubin is below uln) * history or evidence of cirrhosis * platelet count \< 75 × 10\^3/μl * absolute neutrophil count (anc) \< 750/μl * positive screen for hepatitis b or c * known human immunodeficiency virus infection

Keywords: b-cell acute lymphoblastic leukemia (all) pediatric multi-agent chemotherapy jak inhibitor
structured post-marketing surveillance to collect the safety data of intravitreal aflibercept injection (ivt-afl) in patients of wet age-related macular degeneration during real world clinical practice

Conditions: Wet Age-related Macular Degeneration

Summary: the proposed regulatory post-marketing surveillance (pms) study will be planned to collect the safety data of aflibercept intravitreal injection in patients with wet age-related macular degeneration (amd) in real-life treatment practice the primary objective is: - to collect safety data in wet amd patients treated with intravitreal aflibercept injection the secondary objective is: - to determine how disease activity is monitored including type and frequency of ocular tests and frequency of injections

the study will be multicenter, observational, prospective, single arm, post marketing surveillance study of intravitreal aflibercept injection in wet amd patients in routine clinical practice and real-life conditions without any protocol mandated interventions. approximately 100 wet amd patients from up to ten ophthalmology clinics across india will be enrolled in this study. each study site will be requested to enroll approximately 10 patients, however, the sites will be asked to enrolled additional patients in case of failure to enroll 10 patients by other site to complete the recruitment of approximately 100 patients. patients will be observed for maximum period of 6 months after the start of intravitreal aflibercept treatment. the observation period should cover the entire period from initial visit to the last follow-up visit at six months or withdrawal of consent, or the patient is lost to follow up (whatever is earliest). the study site will be asked to enroll into the study all consecutive patients with wet amd for whom the decision has been made to treat with intravitreal aflibercept injection and patients agrees to sign informed consent form for data collection purpose. any switch to another therapy or initiated administration of other anti-vegf (vascular endothelial growth factor) injection in fellow eye or the discontinuation of treatment with ivt-afl before the 6 month implies the end of the observation period. however, the safety follow-up will continue at least 30 days after last intravitreal aflibercept injection or in case of the discontinuation of treatment with ivt-afl or till the patient switch the treatment from ivt-afl and received other anti-vegf injection before the 6 month observation period.

Eligibility criteria:
inclusion criteria: * decision to treat with intravitreal aflibercept injection prior to patient enrolment as per the treating ophthalmologist's routine clinical practice. * adult patients with a diagnosis of wet amd, as an indication approved by the local health authorities (dcgi) for use with intravitreal aflibercept injection. * patient or legal delegate signed informed consent. exclusion criteria: * participation in a clinical trial of an investigational agent within 30 days. * patients receiving other anti-vegf agent in fellow eye. * contraindications according to the local prescribing information.